Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the Clinical Practice Research Datalink
Conclusion
We confirmed the association between elevated LDL-C and MACE. Many patients with ASCVD and elevated LDL-C were untreated with LLT. With the increasing demands on general practitioners, initiatives aimed at improving identification and treatment of at-risk patients within primary care should be considered. (Source: BMJ Open)
Source: BMJ Open - November 29, 2023 Category: General Medicine Authors: Morgan, C. L., Durand, A., McCormack, T., Hughes, E., Berni, T. R., Lahoz, R. Tags: Open access, Cardiovascular medicine Source Type: research
Effect of Combination Therapy with Ezetimibe and Statins versus Statin Monotherapy on Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Conclusions: The effect of ezetimibe on CIMT reduction was shown in non-familial hypercholesterolemia and secondary prevention. These results suggest that the efficacy of ezetimibe may vary with potential CIMT reduction benefits in certain subpopulations.PMID:38004029 | DOI:10.3390/medicina59111980 (Source: Atherosclerosis)
Source: Atherosclerosis - November 25, 2023 Category: Cardiology Authors: Ryuk Jun Kwon Young Hye Cho Eun Ju Park Youngin Lee Sae Rom Lee Jung In Choi Sang Yeoup Lee Soo Min Son Source Type: research
Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial
CONCLUSIONS: Among ASCVD patients, there was no heterogeneity in the effect of moderate-intensity statin plus ezetimibe combination therapy in the higher and lower baseline LDL-C levels for the 3-year composite of cardiovascular outcomes.PMID:37995599 | DOI:10.1016/j.atherosclerosis.2023.117373 (Source: Atherosclerosis)
Source: Atherosclerosis - November 23, 2023 Category: Cardiology Authors: Bom Lee Sung-Jin Hong Seung-Woon Rha Jung Ho Heo Seung-Ho Hur Hyun Hee Choi Kyung-Jin Kim Ju Han Kim Hyun Kuk Kim Ung Kim Yu Jeong Choi Yong-Joon Lee Seung-Jun Lee Chul-Min Ahn Young-Guk Ko Byeong-Keuk Kim Donghoon Choi Myeong-Ki Hong Yangsoo Jang Jung-Su Source Type: research
Bempedoic acid - how will it shape the future lipid-lowering landscape? Mode of action, evidence, and clinical use
Cardiology. 2023 Nov 21. doi: 10.1159/000535372. Online ahead of print.ABSTRACTBackground Low density lipoproteins are now proven to be causal for atherosclerosis. Pharmacological treatment focuses on an increase of LDL receptors, particularly in the hepatocyte, which leads to uptake of LDL from blood, thereby reducing the burden to the arterial wall. This mechanism has first been proven by statins to be effective to reduce cardiovascular morbidity and mortality. The concept of "the lower, the better" was shown by high-intensity statins and new compounds like ezetimibe, PCSK9-antibodies, inclisiran and ultimately bempedoic...
Source: Atherosclerosis - November 21, 2023 Category: Cardiology Authors: Heinz Drexel Arthur Mader Source Type: research
Effect of moderate-intensity statin with ezetimibe combination vs. high-intensity statin therapy according to sex in patients with atherosclerosis
Sci Rep. 2023 Nov 17;13(1):20157. doi: 10.1038/s41598-023-47505-x.ABSTRACTWe aimed to evaluate sex differences in the effects of moderate-intensity statin with ezetimibe combination therapy (rosuvastatin 10 mg plus ezetimibe) versus high-intensity statin (rosuvastatin 20 mg) monotherapy in patients with atherosclerotic cardiovascular disease (ASCVD). This was a sex-specific subgroup analysis of the RACING trial that evaluated the interaction between sex and treatment strategies for the primary outcome (composite of cardiovascular death, major cardiovascular events, or nonfatal stroke at 3 years). Of 3780 patients in the RA...
Source: Atherosclerosis - November 18, 2023 Category: Cardiology Authors: Byung Gyu Kim Seung-Jun Lee Yong-Joon Lee Seng Chan You Soon Jun Hong Kyeong Ho Yun Bum-Kee Hong Jung Ho Heo Seung-Woon Rha Sung-Jin Hong Chul-Min Ahn Byeong-Keuk Kim Young-Guk Ko Donghoon Choi Myeong-Ki Hong Yangsoo Jang Yun-Hyeong Cho Jung-Sun Kim Source Type: research
Effect of moderate-intensity statin with ezetimibe combination vs. high-intensity statin therapy according to sex in patients with atherosclerosis
Sci Rep. 2023 Nov 17;13(1):20157. doi: 10.1038/s41598-023-47505-x.ABSTRACTWe aimed to evaluate sex differences in the effects of moderate-intensity statin with ezetimibe combination therapy (rosuvastatin 10 mg plus ezetimibe) versus high-intensity statin (rosuvastatin 20 mg) monotherapy in patients with atherosclerotic cardiovascular disease (ASCVD). This was a sex-specific subgroup analysis of the RACING trial that evaluated the interaction between sex and treatment strategies for the primary outcome (composite of cardiovascular death, major cardiovascular events, or nonfatal stroke at 3 years). Of 3780 patients in the RA...
Source: Atherosclerosis - November 18, 2023 Category: Cardiology Authors: Byung Gyu Kim Seung-Jun Lee Yong-Joon Lee Seng Chan You Soon Jun Hong Kyeong Ho Yun Bum-Kee Hong Jung Ho Heo Seung-Woon Rha Sung-Jin Hong Chul-Min Ahn Byeong-Keuk Kim Young-Guk Ko Donghoon Choi Myeong-Ki Hong Yangsoo Jang Yun-Hyeong Cho Jung-Sun Kim Source Type: research
Traditional and novel non-statin lipid-lowering drugs
Indian Heart J. 2023 Nov 16:S0019-4832(23)00176-1. doi: 10.1016/j.ihj.2023.11.003. Online ahead of print.ABSTRACTNon-statin drugs find utility in the management of dyslipidaemia in mixed dyslipidaemia, patients with statin intolerance, and when guidelines directed low-density lipoprotein cholesterol (LDL-C) target cannot be achieved despite maximally tolerated statin. The most definite indication of fenofibrate monotherapy is fasting serum triglyceride >500 mg/dl to reduce the risk of acute pancreatitis It offers a modest reduction in cardiovascular events. The statin-ezetimibe combination is commonly used for lipid low...
Source: Indian Heart J - November 18, 2023 Category: Cardiology Authors: Peeyush Jain Source Type: research
Coronary and Extra-coronary Subclinical Atherosclerosis to Guide Lipid-Lowering Therapy
Curr Atheroscler Rep. 2023 Nov 16. doi: 10.1007/s11883-023-01161-8. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: To discuss and review the technical considerations, fundamentals, and guideline-based indications for coronary artery calcium scoring, and the use of other non-invasive imaging modalities, such as extra-coronary calcification in cardiovascular risk prediction.RECENT FINDINGS: The most robust evidence for the use of CAC scoring is in select individuals, 40-75 years of age, at borderline to intermediate 10-year ASCVD risk. Recent US recommendations support the use of CAC scoring in varying clinical scenarios. ...
Source: Atherosclerosis - November 16, 2023 Category: Cardiology Authors: Jelani K Grant Carl E Orringer Source Type: research
